Cargando…
Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis
In the present study, we demonstrated the emergence of dalbavancin non-susceptible and teicoplanin-resistant Staphylococcus aureus small colony variants which were selected in vivo through long-term treatment with dalbavancin. A 36-year-old man presented with a cardiac device-related S. aureus endoc...
Autores principales: | Kussmann, Manuel, Karer, Matthias, Obermueller, Markus, Schmidt, Katy, Barousch, Wolfgang, Moser, Doris, Nehr, Marion, Ramharter, Michael, Poeppl, Wolfgang, Makristathis, Athanasios, Winkler, Stefan, Thalhammer, Florian, Burgmann, Heinz, Lagler, Heimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279813/ https://www.ncbi.nlm.nih.gov/pubmed/30514923 http://dx.doi.org/10.1038/s41426-018-0205-z |
Ejemplares similares
-
Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model
por: Kussmann, Manuel, et al.
Publicado: (2018) -
Different Types of Coagulase Are Associated With 28-Day Mortality in Patients With Staphylococcus aureus Bloodstream Infections
por: Karer, Matthias, et al.
Publicado: (2020) -
Hepatitis E Virus Seroprevalence in Austrian Adults: A Nationwide Cross-Sectional Study among Civilians and Military Professionals
por: Lagler, Heimo, et al.
Publicado: (2014) -
A Longitudinal Seroprevalence Study Evaluating Infection Control and Prevention Strategies at a Large Tertiary Care Center with Low COVID-19 Incidence
por: Schubert, Lorenz, et al.
Publicado: (2021) -
Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections
por: Smith, Jordan R., et al.
Publicado: (2015)